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Available online xxxxAlzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by the pathological accumula-
tion of amyloid beta (Aβ) peptides andneuroﬁbrillary tangles containing hyperphosphorylatedneuronal taupro-
tein. AD pathology is also characterized by chronic brain inﬂammation, which promotes disease pathogenesis. In
this context, the blood-brain barrier (BBB), a highly specialized endothelial cell membrane that lines cerebral
microvessels, represents the interface between neural cells and circulating cells of the immune system. The
BBB thus plays a key role in the generation and maintenance of chronic inﬂammation during AD. The BBB
operates within the neurovascular unit (NVU), which includes clusters of glial cells, neurons and pericytes. The
NVU becomes dysfunctional during AD, and each of its components may undergo functional changes that con-
tribute to neuronal injury and cognitive deﬁcit. In transgenic animals with AD-like pathology, recent studies
have shown that circulating leukocytesmigrate through the activated brain endotheliumwhen certain adhesion
molecules are expressed, penetrating into the brain parenchyma, interacting with the NVU components and po-
tentially affecting their structural integrity and functionality. Therefore, migrating immune system cells in cere-
bral vessels act in concert with the modiﬁed BBB and may be integrated into the dysfunctional NVU. Notably,
blocking the adhesion mechanisms controlling leukocyte–endothelial interactions inhibits both Aβ deposition
and tau hyperphosphorylation, and reducesmemory loss in ADmodels. The characterization of molecularmech-
anisms controlling vascular inﬂammation and leukocyte trafﬁcking could therefore help to determine the basis of
BBB dysfunction during AD and may lead to the development of new therapeutic approaches.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Alzheimer's disease (AD) is a progressive neurodegenerative disor-
der with typical clinical characteristics including amnesic-typememory
impairment, language deterioration, and visuospatial deﬁcits
(Cumming, 2004). AD cognitive and behavioral deﬁcits correlate with
neuronal loss and atrophy, mainly in the hippocampus and neocortex
(Caselli et al., 2006). The central neuropathological hallmarks of AD
are neuronal degeneration, loss of synapses, neuroﬁbrillary tangles,
gliosis and amyloid beta (Aβ) accumulation in senile plaques (Kidd,
1963; Wisniewski and Frangione, 1992; Querfurth and LaFerla, 2010).
Aβ deposition is also observed in the cerebrovasculature, and is usually
described as cerebral amyloid angiopathy (CAA) (Jellinger, 2002;
Viswanathan and Greenberg, 2011). AD pathology is also characterized
by chronic inﬂammation fueled by resident microglial cells and macro-
phages, with the contribution of circulating immune system cells
(Heneka et al., 2015; Zenaro et al., 2015).
Numerous studies suggest that neurovascular dysfunction contrib-
utes to the onset and progression of AD, and propose a link betweenantin).
om).
. This is an open access article under
he blood-brain barrier in Alzcerebrovascular changes and neurodegeneration (Kalaria, 2000;
Farkas and Luiten, 2001; de la Torre, 2004; Viswanathan and
Greenberg, 2011; Zlokovic, 2011; Sagare et al., 2012). Accordingly, re-
cent data conﬁrmage-dependent deterioration of the blood-brain barri-
er (BBB) during normal aging in the human hippocampus, a region
involved in learning and memory, but more accelerated degradation
in patients with mild cognitive impairment (MCI) compared to age-
matched neurologically intact controls, suggesting this phenomenon
contributes to early cognitive impairment (Montagne et al., 2015).
Aβ deposition in the vasculature leads to pro-inﬂammatory and cy-
totoxic events that contribute to the greater BBB permeability in the AD
brain (Roher et al., 2003; Carrano et al., 2011; Erickson and Banks,
2013). Furthermore, CAA is associated with the degeneration of smooth
muscle cells, pericytes and endothelial cells, contributing to the disrup-
tion of the BBB (Erickson and Banks, 2013). Evidence from in vitro stud-
ies and transgenic mouse tauopathy models suggests that tau may also
promote BBB deterioration (Vidal et al., 2000; Forman et al., 2005;
Kovac et al., 2009; Blair et al., 2015). BBB dysfunction correlates with
the appearance of perivascular tau around major hippocampal blood
vessels (Blair et al., 2015). Notably, when tau expression was sup-
pressed, the integrity of the BBB was preserved, suggesting that the
BBB can be stabilized in tauopathic brains by reducing tau levels (Blair
et al., 2015). Both tau and Aβ may therefore promote the loss of BBBthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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inﬂammatory responses. Circulating neutrophils, which migrate in the
brain of AD patients and accumulate in the central nervous system
(CNS) of transgenic mice with AD-like pathology, may also contribute
to vascular dysfunction by adhering and spreading on the brain endo-
thelium and releasing inﬂammatorymediators and neutrophil extracel-
lular traps (NETs) (Zenaro et al., 2015).
In this review, we discuss BBB dysfunction during AD in the context
of the neurovascular unit (NVU), highlighting vascular inﬂammation
mechanisms that contribute to disease pathogenesis. We describe the
roles of the junctional complex, endothelial cells, basal lamina, pericytes
and glial cells in the context of AD pathology. We also emphasize the
role of cell adhesion molecules as markers of endothelial dysfunction
and vascular inﬂammation, and discuss recent data revealing the
emerging role of leukocyte trafﬁcking in BBB and NVU dysfunction dur-
ing AD.
2. Overview of the BBB and NVU
The BBB is a highly specialized endothelial cell membrane lining ce-
rebral microvessels, which regulates the entry of plasma components,
red blood cells and leukocytes into the CNS, and ensures the export of
potentially neurotoxic molecules from the brain to the blood (Abbott
et al., 2006; Zlokovic, 2008; Abbott et al., 2010; Zlokovic, 2011). There
are two further sites in the CNS that form a barrier between the blood
and cerebrospinal ﬂuid (CSF): the arachnoid epithelium forming the
middle layer of the meninges, and the choroid plexus epithelium
(Abbott et al., 2006). At each site, the physical barrier is mainly deter-
mined by tight junctions that reduce the permeability of the intercellu-
lar adhesion areas (Abbott et al., 2006). These unique biological barrier
structures comprise a combination of physical, transport and metabolic
barriers that separate the neural milieu from the blood (Abbott et al.,
2006; Zlokovic, 2008).
Brain microvessel endothelial cells (BMECs) have distinct luminal
(apical) and abluminal (basolateral) membrane compartments that
regulate the physical and functional integrity of the BBB (Betz and
Goldstein, 1978; Daneman and Prat, 2015). BMECs thus support the
three essential functions of the BBB (Daneman and Prat, 2015; ChowFig. 1. Schematic cross-sectional representation of a cerebral capillary. Brainmicrovascular end
cells are linked by tight junctions (TJs), closely surrounded by pericytes and encircled by the
endothelial cells. Astrocyte endfeet processes support endothelial functions and provide the
signals that are detrimental to the BBB.
Please cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
j.nbd.2016.07.007and Gu, 2015): (1) on the apical side, the membrane between CNS en-
dothelial cells establishes a paracellular diffusion barrier to small hydro-
philic molecules and ions (Pappenheimer et al., 1951; Brightman and
Reese, 1969); (2) the passive and active receptors/channels on the lumi-
nal and/or abluminal surfaces regulate the transport of macromolecules
and proteins in and out of the brain (Löscher and Potschka, 2005;
Saunders et al., 2013; Xiao and Gan, 2013); and (3) generally, the
BMECs serve as an interface for communication between the CNS and
periphery, in particular by regulating the entry of circulating immune
system cells into the brain microenvironment (Ransohoff and
Engelhardt, 2012).
The BBB is part of the NVU, together with pericytes, vascular smooth
muscle cells from the vessel wall, neurons and glial cells (Fig. 1)
(Iadecola, 2004; Hawkins and Davis, 2005; Zlokovic, 2005; Abbott et
al., 2010). The NVU controls BBB permeability and cerebral blood ﬂow,
and maintains the chemical composition of the brain interstitial ﬂuid,
which is required to support functional neuronal circuits (Zlokovic,
2011).
BBB/NVU dysfunction has several pathological aspects, including:
(1) the leakage of circulating substances from the plasma into the
CNS; (2) themodulation of transporters leading to an inadequate nutri-
ent supply, the accumulation of toxins in the CNS, or the entry of com-
pounds that are normally excluded; and (3) the altered expression
and/or secretion of proteins by NVU cells, which can promote inﬂam-
mation, oxidative stress and neuronal damage. Current evidence sug-
gests that dysfunctional NVU cells contribute to the development of
several CNS pathologies, including dementia, thus promoting neurode-
generation and cognitive decline during aging and in AD (Deane and
Zlokovic, 2007; Lok et al., 2007; Neuwelt et al., 2008; Bell and
Zlokovic, 2009; Bell et al., 2010; Zlokovic, 2011; Erickson and Banks,
2013).
Historically, the CNS was considered an immunoprivileged organ,
lacking a lymphatic system and shielded from the peripheral circulation
by the BBB. However, it is now clear that the BBB has the ability to re-
spond to soluble factors and plasma proteins, and to communicate
with peripheral immune system cells thus establishing neuro-immune
system interactions, supporting the view that neuroinﬂammation con-
tributes to AD pathology (Quan and Banks, 2007; Heneka et al., 2015).othelial cells are the ﬁrst barrier between blood vessels and brain parenchyma. Endothelial
basal lamina, which is contiguous with the plasma membranes of astrocyte endfeet and
cellular link to neuronal cells. Ramiﬁed microglia can sense neuronal injury and release
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organ and NVU dysfunction should be considered in a broader context,
including peripheral immune cells and circulating soluble molecules
that mediate immune responses (Heneka et al., 2015; Zenaro et al.,
2015).
3. BBB endothelial junctions
Intercellular junctions play fundamental roles in tissue integrity but
also in vascular permeability. The tightly sealed monolayer of endothe-
lial cells forming the BBB is connected at a junctional complex by tight
junctions (TJs) and adherens junctions (AJs) (Wallez and Huber, 2008;
Zlokovic, 2008; Tietz and Engelhardt, 2015). Interendothelial adhesive
proteins control endothelial cell–cell interactions, but some may also
participate in leukocyte transendothelial migration via homophilic or
heterophilic interactions (Muller, 2003; Tietz and Engelhardt, 2015).
3.1. Tight junctions
The TJ is the outermost element of the junctional complex between
two endothelial cells, functioning as a boundary between the apical
and basolateral plasma membrane domains (Bednarczyk and
Lukasiuk, 2011). By physically sealing the paracellular space between
brain capillary endothelial cells, TJs prevent the diffusion of proteins be-
tween the membrane compartments and control cell trafﬁcking from
the blood to the CNS (Zlokovic, 2008; Tietz and Engelhardt, 2015).
This network of sealing proteins includes a series of transmembrane
molecules embedded in the plasma membrane, such as occludin,
claudins and junctional adhesion molecules (JAMs), which in turn are
attached to several cytoskeleton and cytoplasmic scaffold proteins
(Chiba et al., 2008; Bauer et al., 2011). The expression and activity of
TJ proteins and the adaptor molecules linking the TJ to the actin cyto-
skeleton are affected during acute and chronic CNS diseases, suggesting
that themodiﬁcation of TJ components may contribute to disease path-
ogenesis (Petty and Lo, 2002; Persidsky et al., 2006; Bednarczyk and
Lukasiuk, 2011; Gonçalves et al., 2013).
Occludin is a transmembrane protein found in TJs, which anchors
the cytoplasmic zona occludens (ZO) proteins 1 and 2 and the plasma
membranes of adjacent cells (Furuse et al., 1993; Schneeberger and
Lynch, 2004). Claudins form the backbone of TJ strands, whereas
occludin is incorporated into claudin-based strands and appears to reg-
ulate permeability (Förster, 2008). Among the 24 claudin family pro-
teins identiﬁed in mammals, the cerebral microvascular endothelium
expresses only claudins 1, 3, 5 and 12 (Tsukita and Furuse, 1999;
Morita et al., 1999; Liebner et al., 2000; Nitta et al., 2003; Wolburg et
al., 2003). The transmembrane proteins of the TJ associate the cyto-
plasm with peripheral membrane components, which form the large
protein complexes of the membrane-associated guanylate kinase-like
(MAGUK) family (Hawkins and Davis, 2005). ZO-1 binds directly to
many TJ proteins in vitro (including occludin and claudins) and orches-
trates the formation of TJ complexes (Fanning et al., 1998). Occludin,
claudin-5 and ZO-1 are considered to be sensitive indicators of structur-
al changes in the BBB during disease pathogenesis (Yang and
Rosenberg, 2011; Naik et al., 2014).
Several studies have shown that Aβ is responsible for changes in the
TJ proteins that disrupt the physiological function of the BBB in AD pa-
tients (Marco and Skaper, 2006; Kook et al., 2012; Wan et al., 2015).
When endothelial cells isolated from rat cerebral cortex microvessels
were treated with Aβ1-42, occludin expression was suppressed and
both claudin-5 and ZO-2 were redistributed to the cytoplasm, whereas
in untreated cells occludin, claudin-1/5 and ZO-1/2 were distributed
continuously along the plasma membrane at cell–cell contacts (Marco
and Skaper, 2006). In other studies, Aβ1-42 oligomers were shown to
disrupt TJs and increase vascular permeability by suppressing the ex-
pression of ZO-1, claudin-5 and occludin, and by inducing the expres-
sion of the matrix metalloproteases (MMP)-2 and MMP-9 inPlease cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
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2012; Wan et al., 2015). Aβ is toxic in vitro to brain endothelial cells be-
cause it binds to the receptor for advanced glycation end products
(RAGE) and induces the production of reactive oxygen species (ROS),
which ultimately disrupt TJs and reduce BBB integrity (Carrano et al.,
2012). Consistent with these in vitro ﬁndings, cerebral capillaries were
found to be disrupted near Aβ deposits togetherwith elevated RAGE ex-
pression and enhanced MMP secretion in the microvessels of 5xFAD
mice, an animalmodel of AD characterized bymassive Aβ accumulation
in the brain at early stages of the disease (Kook et al., 2012). Further-
more, the expression of occludin, claudin-5, and ZO-1was strongly sup-
pressed in the Aβ-laden capillaries of patients with capillary CAA,
suggesting that the modulation of TJ protein expression may increase
vascular permeability in the AD brain (Carrano et al., 2011; Carrano et
al., 2012).
JAMs are members of the immunoglobulin (Ig) superfamily. There
are three variants (JAM-A, JAM-B and JAM-C) and they primarily under-
go homophilic interactions, e.g. JAM-A on the surface of one endothelial
cell will bind to JAM-A on the surface of its neighbor (Garrido-Urbani et
al., 2014). However, JAMs also engage leukocyte integrins in a
heterophilic manner, and may participate in leukocyte extravasation
during inﬂammatory responses (Del Maschio et al., 1999; Ostermann
et al., 2002; Santoso et al., 2002; Muller, 2003). In vitro studies have
shown that Aβ1-42 suppresses the expression of JAM-C in human um-
bilical vein endothelial cells (HUVECs), but it is unclear whether this is
also the case in vivo and the involvement of JAMs in AD therefore re-
mains to be clariﬁed (Chao et al., 2016).
3.2. Adherens junctions
Cadherins aremembrane-spanningproteins thatmediate intercellu-
lar adhesion in AJs, the inner element of the junctional complex be-
tween two endothelial cells (Zlokovic, 2008; Bednarczyk and
Lukasiuk, 2011; Tietz and Engelhardt, 2015). The principal cadherin is
vascular endothelial (VE) cadherin, a homophilic adhesionmolecule lo-
cated on the lateral endothelial cell surface. VE-cadherin expressionwas
recently shown to be reduced in brain vessels that accumulate ﬁbrino-
gen-Aβ (Fg-Aβ) complexes in a model of hyperhomocysteinemia, a pa-
thology that may accompany cognitive disorders including AD
(Muradashvili et al., 2014). These data suggest that Aβ binding toﬁbrin-
ogen can also exacerbate cerebrovascular permeability during AD, by
modulating VE-cadherin levels in cerebral microvessels (Muradashvili
et al., 2014). Real-time observation of neutrophil transmigration in
vitro across endothelial cell monolayers expressing VE-cadherin fused
to green ﬂuorescent protein (GFP) revealed that these cells transmi-
grate at regions of low VE-cadherin expression (Shaw et al., 2001).
Moreover, the in vivo administration of antibodies that block the adhe-
sive function of VE-cadherin increases vascular permeability and accel-
erates the recruitment of neutrophils to inﬂammation sites (Gotsch et
al., 1997; Corada et al., 1999). Therefore,we hypothesize that neutrophil
transmigration into the CNS, as observed in mouse models of AD, may
take place in brain microvessels with low levels of VE-cadherin
(Zenaro et al., 2015).
4. Endothelial cells
The brain vasculature of AD patients is characterized by a greater
prevalence of collapsed or degenerated endothelium, and more severe
impairment of BBB transport systems, compared to age-matched con-
trol subjects (Kalaria and Hedera, 1995; Zlokovic, 2008). For example,
glucose transporter GLUT1 is expressed at lower levels in the brain cap-
illaries of AD patients andmousemodels of AD than corresponding age-
matched controls, suggesting that the AD brain suffers a chronic short-
age of energy-rich metabolites (Kalaria and Harik, 1989; Simpson et
al., 1994; Mooradian et al., 1997; Farkas and Luiten, 2001; Hooijmans
et al., 2007; Merlini et al., 2011). Recently, it has been shown thatheimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
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works, blood ﬂow and BBB integrity as well as neuronal function
(Winkler et al., 2015). GLUT1 deﬁciency in endothelial cells leads to
BBB breakdown with extravascular accumulation of ﬁbrin and IgG in
brain parenchyma and reduction of TJ proteins in AD mice, suggesting
a role for GLUT1 decrease on endothelial cells in AD pathogenesis
(Winkler et al., 2015). Several studies using F-2-ﬂuoro-2-deoxy-D-glu-
cose-PET (FDG-PET) have demonstrated that MCI patients take up less
glucose at the BBB, and FGD-PET may therefore be used as a marker
for the preclinical diagnosis of AD (Hunt et al., 2007; Samuraki et al.,
2007; Mosconi et al., 2008). Moreover, these studies suggest that re-
duced glucose uptake across the BBB may precede the neurodegenera-
tive process and brain atrophy that occurs when MCI converts to AD.
Aβ peptides also cross BMECs to and from the brain by active trans-
port, so the altered expression of Aβ peptide transporters in endothelial
cells could contribute to the accumulation of Aβ (Zlokovic et al., 2010).
BMECs express low density lipoprotein receptor related protein 1
(LRP1) as well as RAGE, which play opposing roles: LRP1 mediates the
efﬂux of Aβ from the brain to the periphery, whereas RAGE is thought
to promote Aβ inﬂux back into the CNS (Deane et al., 2004; Pﬂanzner
et al., 2010; Sagare et al., 2012). Clinical studies have demonstrated
that AD pathology correlates with lower LRP1 levels and higher RAGE
levels, which promotes the accumulation of Aβ peptides in the brain pa-
renchyma (Donahue et al., 2006; Zlokovic, 2008; Deane et al., 2012). A
recent study has shown that 1,25(OH)D3, the active form of vitamin D,
has a neuroprotective effect during AD pathogenesis by inducing the
clearance of Aβ, which is achieved by inducing LRP1 expression and re-
ducing the expression of RAGE in brain endothelial cells (Guo et al.,
2016). Accordingly, 5xFAD mice lacking the LRP1 receptor show much
lower plasma levels of Aβ1-42, whereas the levels of soluble Aβ in the
brain increased sharply (Storck et al., 2016). Aβ oligomers can directly
upregulate the expression of RAGE in endothelial cell lines (Wan et al.,
2015) and their binding to RAGE triggersmultiple cellular signaling cas-
cades in BMECs. For example, the Aβ–RAGE interaction induces MMP-2
expression and reduces P-glycoprotein (P-gp) expression in vitro (Du et
al., 2012; Park et al., 2014). P-gp is an ATP-dependent efﬂux transporter
that transports Aβ out of the brain, and its expression in the brain endo-
thelium of 5xFAD mice is suppressed near Aβ plaques (Demeule et al.,
2001; Lam et al., 2001; Kuhnke et al., 2007; Park et al., 2014). Further-
more, recent studies have shown that β-secretase 1 enzyme (BACE1)
is more abundant on the BMECs of AD mice (hAPPSL model) than
healthy controls, suggesting a role for BACE-1 the accumulation of Aβ
in blood vessels (Devraj et al., 2015). Collectively, these results suggest
that the accumulation of Aβ in blood vessels and the induction of CAA
are promoted by the overexpression of Aβ by endothelial cells and the
altered expression and function of Aβ transporters on BMECs.
Other vascular-speciﬁc molecular pathways may contribute to AD
pathogenesis, such as homeodomain-transcription factor GAX encoded
by MEOX2 (mesenchyme homeobox 2) gene. Previous studies have
shown that deletion ofMEOX2 leads to reduction of brain capillary den-
sity and cerebral blood ﬂow, loss of the angiogenic response to hypoxia
in the brain and reduced LRP1 expression in a mouse model of AD (Wu
et al., 2005). RestoringMEOX2 gene expression in brain endothelial cells
obtained from individuals with AD stimulates angiogenesis, suppresses
AFX1 forkhead transcription factor–mediated apoptosis and increases
the levels of LRP1 and its receptor-associated protein (RAP), further
supporting a role for GAX in AD (Wu et al., 2005). Moreover, in AD sub-
jects, vascular smooth muscle cells (VSMC) in small pial and intracere-
bral arteries express high levels of serum response factor (SRF) and
myocardin (MYOCD), two interacting transcription factors that orches-
trate a VSMC-differentiated phenotype, which in turn leads to a hyper-
contractile phenotype in small cerebral arteries causing reduction in the
cerebral blood ﬂow and decreased Aβ clearance (Chow et al., 2007; Bell
et al., 2009).
Oxidative stress is also considered a pivotal mechanism leading to
cerebrovascular dysfunction in AD, and ROS act as signaling moleculesPlease cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
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apoptosis, and senescence in endothelial cells (Frey et al., 2009).
NADPH oxidases, the major source of ROS in blood vessels, are respon-
sible for the cerebrovascular dysregulation induced by Aβ1-40 in the
blood vessels of Tg2576 mice, an animal model of amyloid pathology
(Park et al., 2005).Moreover, a recent investigation in 3xTg-ADmice re-
vealed that thrombin, a mediator of cerebrovascular inﬂammation and
oxidative stress, signiﬁcantly increases the cerebrovascular expression
of inﬂammatory proteins and ROS, and that the inhibition of thrombin
blocks the generation of ROS induced by hypoxia (Tripathy et al.,
2013). Therefore, ROS production by brain endothelial cells in response
to hypoxia is a detrimental mechanism that probably contributes to AD
pathogenesis (Feng and Wang, 2012).
Other inﬂammatory mediators may play a role in BBB dysfunction
during the progression of AD. Brain microvessels from AD patients se-
crete higher levels of several inﬂammatory mediators (such as nitric
oxide, pro-inﬂammatory cytokines, chemokines, prostaglandins and
MMPs) and express leukocyte adhesion molecules, clearly indicating
pro-inﬂammatory changes in the vasculature (Grammas et al., 2011).
In particular, interleukin 17 (IL-17) has previously been shown to in-
duce BBBdamage in vitro, and our recent data show that neutrophilsmi-
grating into the brains of AD-like mice secrete this cytokine, suggesting
it plays a role in endothelial dysfunction during AD (Kebir et al., 2007;
Zenaro et al., 2015).
5. Basement membranes
Two basement membranes can be distinguished at the level of CNS
microvessels: an endothelial basement membrane beneath the endo-
thelial cells, and an astroglial basement membrane, which underlies
the astrocytic endfeet (Engelhardt and Sorokin, 2009). Theﬁrst and con-
tains ﬁbronectin, type IV collagen, perlecan, and laminins 4 and 5,
whereas the second comprises ﬁbronectin, agrin and laminins 1 and 2
(Sixt et al., 2001; Engelhardt and Sorokin, 2009). The astroglial base-
ment membrane, together with the leptomeningeal basement mem-
brane, constitutes the parenchymal basement membrane, which
delineates the neuropil. The endothelial and parenchymal basement
membranes are clearly distinguishable in the postcapillary venules,
whereas in brain capillaries they fuse to form one basement membrane
structure (Figs. 1 and 2) (Bechmann et al., 2007; Engelhardt and
Sorokin, 2009). The extracellular matrix (ECM) structural proteins of
the BBB basement membranes establish the essential physical scaffold-
ing for cells and therefore support the assembly of TJs (Tilling et al.,
1998; Savettieri et al., 2000).
Previous studies have identiﬁed thinning and discontinuities within
the vascular basementmembrane in AD patients, suggesting that signif-
icant ECM changes occur during AD (Zipser et al., 2007; Farrall and
Wardlaw, 2009). The expression of collagen IV, perlecan andﬁbronectin
in the basement membrane-associated ECM of subclinical and clinical
AD patients increased in the frontal and temporal cortices compared
to controls and positively correlated with Aβ deposition, suggesting
that changes affecting the brainmicrovascular structure could drive dis-
ease pathogenesis (Lepelletier et al., 2015).
Alterations in the structure and organization of basement mem-
brane ECM proteins such as laminins may favor the migration of circu-
lating leukocytes into the brain during inﬂammation. After the initial
penetration of the endothelial cell monolayer, extravasating leukocytes
need to traverse the endothelial basement membrane. Laminin 4 is lo-
calized in all endothelial basement membranes, whereas laminin 5 is
predominantly found in the walls of capillaries and postcapillary ve-
nules, the sites of leukocyte extravasation (Hallmann et al., 2005). The
role of ECM proteins in leukocyte trafﬁcking during AD is unknown,
but insight gained from other CNS inﬂammatory diseases may provide
useful information. For example, in mice with experimental autoim-
mune encephalomyelitis (EAE), amodel ofmultiple sclerosis, T cells mi-
grate across laminin α4 whereas laminin α5 inhibits their migrationheimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
Fig. 2. Schematic representation of neutrophil extravasation in postcapillary venules and potential CNS damage. Aβ and other inﬂammatory stimuli promote the activation of cerebral
endothelium and immune system cells. The activated endothelium in brain venules upregulates the expression of adhesion molecules and chemoattractants supporting the adhesion
of neutrophils that transmigrate into the brain parenchyma. Neutrophils adhered on activated endothelium may acquire a toxic phenotype, releasing reactive oxygen species (ROS),
cytokines, chemokines and enzymes contributing to the destruction of the BBB. Neutrophils may also release neutrophil extracellular traps (NETs) comprising decondensed chromatin
and active proteases that may damage the BBB. Migrated neutrophils and microglia may sustain their reciprocal activation, resulting in chronic inﬂammation and neuronal
degeneration. Intraparenchymal neutrophils may be toxic towards neuronal and glial cells and may promote synaptic dysfunction, Aβ deposition and tau hyperphosphorylation.
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ing laminin 8 are permissive for T cell transmigration in mice with EAE,
whereas those containing laminin 10 are restrictive (Sixt et al., 2001).
The subsequent penetration of the parenchymal basement membrane
containing laminins 1 and 2 by activated T cells occurs only after the dis-
ruption of this outer barrier, probably via the release ofMMPs (Graesser
et al., 1998).
Secreted MMPs cleave protein components of the ECM and have
been implicated in many brain disorders associated with BBB injury, in-
cluding AD (Agrawal et al., 2006; Hu et al., 2009; Stomrud et al., 2010;
Qiu et al., 2011; Yang and Rosenberg, 2011; Zhang et al., 2012;
Barichello et al., 2014;Wan et al., 2015). MMP-2 andMMP-9 can digest
the endothelial basal lamina and TJ scaffold proteins, which are neces-
sary for BBB integrity (Qiu et al., 2011; Zhang et al., 2012). MMP-2 and
MMP-9 have a high afﬁnity for dystroglycan, which anchors laminins
1 and 2, and these enzymes are required for T cells to penetrate through
the parenchymal basal membrane (Agrawal et al., 2006). Under
neuroinﬂammatory conditions, MMP-3 also contributes to the disrup-
tion of the BBB by attacking TJ and basal lamina proteins, facilitating
neutrophil migration into the brain (Gurney et al., 2006). MMP-3 and
MMP-9 are more abundant in the CSF of AD patients than controls,
and may be involved in ECM degradation and AD pathogenesis
(Stomrud et al., 2010). Interestingly, neutrophils, which have recently
been shown tomigrate in the AD brain, contain preformedMMP-9 pro-
teins in their granules, which can be released during transendothelial
migration, leading to basement membrane damage (Opdenakker et
al., 2001; Noble et al., 2002; Zenaro et al., 2015).Moreover, Aβ1-42 olig-
omers can trigger a signiﬁcant increase in the expression of MMP-2 and
MMP-9 in bEnd.3 cells in vitro (Wan et al., 2015).We therefore hypoth-
esize that the higher levels of circulating or perivascular Aβ in ADPlease cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
j.nbd.2016.07.007patients and transgenic animals with AD-like disease, as well as
the accumulation of leukocytes adhering to the vascular wall or
transmigrating into the neuropil, may contribute to basement mem-
brane degradation and BBB dysfunction.
6. Pericytes
Pericytes are recruited to the nascent vessels during embryogenesis
more than a week before astrocytes emerge, and they are necessary for
the formation of the BBB (Daneman et al., 2010). They regulate several
functions of the BBB, including the formation of TJs and vesicle trafﬁck-
ing in the CNS, and they inhibit the accumulation of molecules that in-
crease vascular permeability and the inﬁltration of the CNS by
immune system cells (Daneman et al., 2010). Pericytes also maintain
the structural stability of microvessels, clear the CNS of toxic cellular
byproducts, and regulate the blood ﬂow through brain capillaries by
controlling cellular contraction/relaxation (Peppiatt et al., 2006;
Dore-Duffy, 2008; Sagare et al., 2013).
Pericyte-deﬁcient mice show an age-dependent reduction in cere-
bral microcirculation, and the BBB deteriorates leading to neurodegen-
eration and cognitive impairment (Bell et al., 2010). In support of the
data from experimental animals, age-dependent BBB degradation was
also observed in the hippocampus of MCI patients compared to control
subjects, correlating with injury to BBB-associated pericytes and in-
creased BBB permeability in the CA1 and DG sectors (Montagne et al.,
2015). Interestingly, the analysis of CSF biomarkers revealed higher
levels of soluble platelet-derived growth factor receptor β (sPDGFRβ),
a marker of pericyte injury, in MCI patients compared to control sub-
jects, whereas no other signs of endothelial or neural injury, or tau
and Aβ pathology, were observed (Montagne et al., 2015).heimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
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al., 2010; Zlokovic, 2011; Bell et al., 2012; Sagare et al., 2013; Sengillo
et al., 2013;Winkler et al., 2014;Montagne et al., 2015). AD patients suf-
fer a signiﬁcant loss of pericytes in the cortex and hippocampus com-
pared to control subjects, correlating with the severity of BBB
degradation (Sengillo et al., 2013). Aβ deposition in cerebral vessels is
associated with pericyte and smooth muscle cell degeneration
(Verbeek et al., 2000) and the direct treatment of acute hippocampal
slices with Aβ42 oligomers increases the production of ROS by
pericytes, which accelerates their loss (Veszelka et al., 2013). In addi-
tion, recent in vitro data indicate that Aβ deposits are associated with
the shedding of PDGFRβ from primary cultures of human pericytes, fur-
ther suggesting that Aβ contributes to pericyte degeneration in AD
(Montagne et al., 2015). Moreover, LRP1 and other Aβ-binding recep-
tors such as the low density lipoprotein receptor (LDLR), RAGE, and
CD36 are expressed on pericytes from post-mortem AD brains associat-
ed with cerebral amyloid angiopathy (Wilhelmus et al., 2007a). The in
vitro treatment of human pericytes with Aβ induces the expression of
LRP-1 and LDLR, suggesting that these receptors are involved in the
Aβ-mediated death of cerebral perivascular cells (Wilhelmus et al.,
2007a, 2007b). Pericyte deﬁciency in APPsw/0 Pdgfrβ+/−mice acceler-
ates the deposition of Aβ plaques in the brain parenchyma and blood
vessels compared to normal amyloid precursor protein (APP) mice
(Sagare et al., 2013). Notably, APPsw/0 Pdgfrβ+/−mice normally present
amyloid pathology alone, but also accumulate hyperphosphorylated tau
species resulting in tau aggregates and neuronal loss during the early
stages of the disease, suggesting that pericyte deﬁciency favors the de-
velopment of tau pathology (Sagare et al., 2013).
Previous studies have shown that lack of murine Apoe and expres-
sion of APOE4 gene, a major genetic risk factor for AD, but not APOE2
and APOE3, leads to BBB dysfunction by activating a proinﬂammatory
cyclophilin A (CypA)–nuclear factor-κ B–matrix-metalloproteinase-9
pathway in mouse pericytes (Bell et al., 2012). Interestingly, Apoe−/−
andAPOE4mice also showa reduction of TJ proteins and develop vascu-
lar defects before neuronal and synaptic changes occur (Bell et al.,
2012). In support of these data, recent studies using postmortem
human brain tissues have shown that APOE4 compared with APOE3 ac-
celerates pericyte loss in AD, which correlates with the magnitude of
BBB breakdown to plasma proteins immunoglobulin G and ﬁbrin
(Halliday et al., 2016).APOE4 comparedwith APOE3 leads to a higher ac-
cumulation of CypA andMMP-9 in pericytes and endothelial cells in AD
suggesting a role for LRP1-dependent CypA–MMP-9 BBB degrading
pathway in accelerated BBB breakdown in AD APOE4 compared with
AD APOE3 carriers (Halliday et al., 2016).
Recent studies have also implicated pericytes in brain immune re-
sponses, including the regulation of leukocyte trafﬁcking to the CNS
(ElAli et al., 2014; Hill et al., 2014). Mice defective in pericyte develop-
ment express higher levels of intercellular adhesion molecule 1
(ICAM-1) on the brain endothelium, and larger numbers of Gr1+ leuko-
cytes inﬁltrate into the brain parenchyma, suggesting a role for
pericytes in leukocyte trafﬁcking in the CNS (Daneman et al., 2010). Ac-
cordingly, recent intravital microscopy studies in inﬂamed cremasteric
venules have shown that neutrophils exhibit abluminal crawling along
pericyte processes to gaps between adjacent pericytes with almost no
crawling observed on pericyte-deﬁcient regions (Proebstl et al., 2012).
Neutrophil-pericyte adhesion interactions in these studies were medi-
ated by ICAM-1, LFA-1 and macrophage-1 antigen (Mac-1) (Proebstl
et al., 2012). Furthermore, pericytes can sense inﬂammation and dan-
ger-associated molecular patterns (DAMPs), and in turn upregulate ad-
hesionmolecules, whichmediate adhesive interactionswith cells of the
innate immune system (Stark et al., 2013). In response to tumor necro-
sis factor (TNFα), N-formyl-methionyl-leucyl-phenylalanine (fMLP) or
lysates of necrotic cells, pericytes may acquire a pro-inﬂammatory phe-
notype, characterized by higher ICAM-1 levels and the secretion of sig-
niﬁcantly greater amounts of chemoattractants such as CXCL1, CXCL8,
macrophage migration inhibitory factor (MIF), CCL2 and IL-6 (Stark etPlease cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
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pendent pericyte–leukocyte interactions, thus modulating innate im-
mune responses during the sterile inﬂammation that occurs in AD.
Indeed, Aβ is a clinically relevant endogenous danger signal sensed by
formyl peptide receptor 1 (FPR1), LRP1, LDLR, RAGE and CD36, which
are expressed on pericytes in post-mortem AD brains (Yan et al.,
1996; Wilhelmus et al., 2007a, 2007b; Stewart et al., 2010). Based on
these studies and our recent data showing neutrophil accumulation in
AD, we speculate that Aβ triggers pro-inﬂammatory signals through
these receptors in pericytes, promoting leukocyte recruitment in AD
(Zenaro et al., 2015). The role of pericytes in neurovascular dysfunction
is still not well understood and future studies are required to determine
the molecular mechanisms underlying pericyte impairment and their
inﬂuence on neighboring cells within the NVU during AD.
7. Glial cells and perivascular macrophages
Astrocytic perivascular endfeet surround ~98% of the parenchymal
basal membrane of brain microvessels, with microglial ramiﬁcations
covering the remaining surface. Astrocytes also communicatewith neu-
rons, establishing a link for endothelial–neuronal coupling (Fig. 1). As-
trocytes can upregulate many BBB features, leading to tighter TJs
(physical barrier), the expression and polarized localization of trans-
porters (transport barrier), and specialized enzyme systems (metabolic
barrier) (Abbott et al., 2006).
Studies of AD brain cortex biopsies have revealed speciﬁc ultrastruc-
tural changes in astrocytes near Aβ deposits both in the brain parenchy-
ma and cerebrovasculature (Wisniewski et al., 1989). Accordingly, in
transgenic mice with both arctic and Swedish APP mutations (Arc/
SweAβ), which are characterized by strong CAA pathology, astrocyte
endfeet surrounding vascular Aβ deposits showed morphological
changes including retraction and swelling and reduction expression of
GLUT1 and lactate transporters (Merlini et al., 2011). These changes
occur at early stages of the disease and are consistent with NVU
uncoupling, suggesting that astrocyte dysfunction can contribute to
the early behavioral and cognitive impairments seen in Arc/SweAβ
mice.
The uptake and degradation of Aβ by astrocytes in the NVU is medi-
ated by the expression of aquaporin-4 (AQP4), which is abundant in as-
trocytic processes adjacent to cerebral microvessels (Hoshi et al., 2012;
Yang et al., 2012). Animals lackingAQP4 in their astrocytes are unable to
clear soluble Aβ efﬁciently, suggesting that this pathway may remove
Aβ from the CNS (Iliff et al., 2012). In the Arc/SweAβ mouse model of
AD, changes in AQP4 expression emerge just after the appearance of
the ﬁrst Aβ plaques (Yang et al., 2011). The reallocation of AQP4 from
endfoot membranes at sites of perivascular Aβ deposits to non-endfoot
membrane domains in the neuropil surrounding Aβ plaques potentially
causes astrocyte depolarization (Yang et al., 2011). These data suggest
that the aggregation of Aβ deposits in blood vessels disrupts the
perivascular sheath of astrocyte processes and interferes with the
mechanisms that are normally responsible for the anchoring of
perivascular AQP4 molecules (Yang et al., 2011). Accordingly, the loss
of astrocyte polarizationwas recently observed in 5XFADmice, together
with lower expression levels of AQP4 and the astrocyte-derived base-
ment membrane component laminin α2 compared to wild-type con-
trols (Park et al., 2014).
The proposed immunoactive properties of astrocytes are still a mat-
ter of debate. However, several recent reports suggest that astrocytes
actively contribute to the immune responses at the NVU, especially by
integrating signals from the periphery and the brain. At the site of neu-
roinﬂammation, astrocyte-derived cytokines and chemokines play both
immunoregulatory and pro-inﬂammatory roles in brain lesions. Non-
stimulated human astrocytes in culture express cytokines and
chemokines such as granulocyte and granulocyte-macrophage colony
stimulating factors (G-CSF, GM-CSF), CXCL1, IL-6, IL-8 (CXCL8), mono-
cyte chemoattractant protein 1 (MCP-1/CCL2) and MIF (Choi et al.,heimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
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the cytokines most frequently associated with neuroinﬂammation, cul-
tured human astrocytes produce IL-1β, IL-1ra, TNFα, interferon gamma-
induced protein 10 (IP-10/CXCL10), macrophage inﬂammatory protein
1 alpha (MIP-1α/CCL3), and regulated on activation, normal T cell
expressed and secreted (RANTES/CCL5), in addition to soluble ICAM-1
(sICAM-1) and complement component 5 (Choi et al., 2014). Together,
these data indicate that soluble factors released by astrocytes may pro-
mote the trafﬁcking of cells related to innate and acquired immunity in
the CNS (Choi et al., 2014). Notably, IL-8 is a potent chemoattractant
that draws neutrophils to sites of inﬂammation, and higher levels of
this molecule are found in the CSF of MCI and AD patients compared
to healthy controls (Galimberti et al., 2006; Galimberti et al., 2008). Fur-
thermore, we have recently reported the presence of neutrophils pro-
ducing IL-17 in the brain of mouse AD models at early stages of the
disease (Zenaro et al., 2015) and these results, togetherwith data show-
ing that astrocyte stimulation with IL-17 increases the expression of
pro-inﬂammatory molecules and neutrophil-mobilizing cytokines and
chemokines including GM-CSF, CXCL1 (KC), CXCL2 (MIP-2), CCL20
and MMP9 (Kang et al., 2010), suggest that neutrophil–astrocyte inter-
play may promote neuroinﬂammation during AD (Fig. 2).
Microglial cells and perivascular macrophages are the two main im-
mune system cell populations in the CNS. In their basal state these cells
may be distinguished by their location, phenotype andmorphology, but
following activation it is difﬁcult to discriminate between these cell
populations (Guillemin and Brew, 2004; Hanisch, 2013; Harry, 2013;
Cartier et al., 2014; Fu et al., 2014). The plasticity of these cells and
their ability to transition between activation states is reﬂected by their
complicated and heterogeneous phenotypes (Cameron and Landreth,
2010). Therefore, some functions attributed to perivascular microglia
may be carried out by perivascular macrophages. Some microglial cells
are found in the NVU, suggesting thatmicrogliamay inﬂuence endothe-
lial cells and contribute to the function of the BBB (da Fonseca et al.,
2014). However, blood-derived human macrophages in a BBB cell
culture model also interact with the cerebral endothelium and mod-
ulate BBB-speciﬁc functions (Zenker et al., 2003). Furthermore, some
studies have shown that perivascular macrophages rather than resi-
dent microglia are responsible for the physiological degradation of
Aβ, a function that has been previously attributed to microglial
cells (El Khoury et al., 2007; Hawkes and McLaurin, 2009; Malm et
al., 2010).
Microglia are involved in the active surveillance of the CNS and con-
tinuously scan the environment to detect pathogens or tissue damage
(Yang et al., 2011). The activation of microglia induces an innate im-
mune response dominated by the release of pro-inﬂammatory cyto-
kines and chemotactic factors that may act on circulating leukocytes
(Heneka, 2015). Several reports indicate that microglia promote the
sustained migration of lymphocyte and monocytes through the BBB
into the CNS during brain inﬂammation (Persidsky et al., 1999;
Hudson et al., 2005; Lécuyer et al., 2016).
Microglia may initially play a protective role in AD by facilitating the
clearance of Aβ, whereas at later disease stages the chronic activation of
microglia is accompanied by diminished phagocytosis and the more
abundant secretion of pro-inﬂammatory cytokines, leading to the accu-
mulation of Aβ and the ampliﬁcation of neuroinﬂammation (El Khoury
et al., 2007; Hickman et al., 2008; Krabbe et al., 2013; Heneka et al.,
2015). During AD, the activation of microglia in response to neuronal
damage and Aβ also becomes a chronic source of ROS, which causes
neurotoxicity and the impairment of BBB function, including the reorga-
nization of TJs and restricted transendothelial electrical resistance
(Block, 2008; Sumi et al., 2010). Furthermore, IL-1β, amajor pro-inﬂam-
matory cytokine released from activated microglia, increases the per-
meability of the BBB and abolishes the ability of astrocytes to maintain
BBB integrity (Wang et al., 2014). IL-1β also promotes neutrophil trans-
migration in a BBBmodel, establishing a link betweenmicroglial activa-
tion and neutrophil trafﬁcking through the BBB, which was recentlyPlease cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
j.nbd.2016.07.007described in AD transgenic mice and AD patients (Allen et al., 2012;
Zenaro et al., 2015).
Several reports have revealed vascularﬁbrin and ﬁbrinogen deposits
coincident with areas of BBB permeability and Aβ deposition,
suggesting that ﬁbrinogen/ﬁbrin-Aβ interactions may exacerbate
neurovascular damage and promote cognitive impairment through
perivascular microglial activation (van Oijen et al., 2005; Paul et al.,
2007; Xu et al., 2008; Ryu and McLarnon, 2009; Cortes-Canteli et al.,
2010). In agreementwith this hypothesis, recent two-photonmicrosco-
py data in an EAE model have shown that ﬁbrinogen leaking from the
blood engages the microglial integrin receptor CD11b/CD18 and in-
duces the rapid formation of microglial perivascular clusters on the vas-
culature, leading to axonal damage and neuroinﬂammation (Davalos et
al., 2012). Fibrinogen also causes the activation of microglial cells in ex-
perimental stroke models, resulting in the upregulation of inﬂammato-
ry proteins and the appearance of intracellular vesicles containing
particles that express CD31+, a blood vessel marker, suggesting that
perivascular microglia can internalize and break down endothelial
cells (Jolivel et al., 2015). Perivascular microglia therefore promote the
disintegration of the BBB and therapeutic approaches that inhibit
microglial activationmay have a beneﬁcial effect in neuroinﬂammatory
diseases.
8. Vascular adhesion molecules as markers of endothelial
dysfunction
The expression of vascular adhesion molecules that mediate leuko-
cyte trafﬁcking is minimal or undetectable under physiological condi-
tions, with P-selectin, E-selectin and ICAM-1 immunoreactivity
detected in pial and choroid plexus venules in the normal brain
(Kivisäkk et al., 2003). However, during brain inﬂammation, the expres-
sion of endothelial adhesionmolecules increases strongly, and their sol-
uble forms are released into the circulation to provide biomarkes of
endothelial dysfunction and vascular inﬂammation (Bö et al., 1996;
Jander et al., 1996; Stins et al., 1997; Alvarez et al., 2011; Staykova et
al., 2000; Garton et al., 2006; Rossi et al., 2011).
Two main classes of adhesion molecules are associated with micro-
vascular endothelial activation: integrin ligands from the immunoglob-
ulin (Ig) superfamily and endothelial selectins (Rossi et al., 2011).
Vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1 belong to
the ﬁrst class and act as ligands for the very late antigen 4 (VLA-4)
and LFA-1 integrins, respectively, with VCAM-1 exclusively expressed
on endothelial cells and ICAM-1 also expressed on leukocytes (Rossi et
al., 2011). The second class of endothelial adhesion molecules is repre-
sented by E-selectin and P-selectin, with E-selectin exclusively present
on endothelial cells and P-selectin also located togetherwith Aβ precur-
sor proteins in platelet α-granules (Rossi et al., 2011; Vignini et al.,
2011; Järemo et al., 2013; Vignini et al., 2013). The upregulation of
selectins and integrin ligands on the endothelium is regulated by cyto-
kines, hormones, cellular stress and other factors (Carlos and Harlan,
1994; Roebuck and Finnegan, 1999; Vestweber and Blanks, 1999; Ley,
2003).
Higher levels of soluble VCAM-1, ICAM-1, E-selectin and P-selectin
are found in plasma samples fromAD patients compared to control sub-
jects, suggesting that vascular inﬂammation occurs during AD (Rentzos
et al., 2005; Nielsen et al., 2007; Zuliani et al., 2008; Huang et al., 2015;
Järemo et al., 2013). Notably, higher levels of soluble VCAM-1 correlate
with more advanced dementia, including poor short-termmemory and
visuospatial functions, as well as with changes in white matter
hyperintensities observed during magnetic resonance imaging (MRI),
suggesting VCAM-1 could be used as a biomarker for cognitive decline
during AD (Huang et al., 2015). However, soluble E-selectin levels are
inversely correlated with the tau/Aβ1-42 ratio in the CSF and E-selectin
is more abundant in AD patients without the typical CSF biomarker sig-
nature, suggesting it may be useful as a biomarker for vascular dysfunc-
tion concurring with dementia (Li et al., 2015). In addition to selectinsheimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
Fig. 3. Leukocytes migrate in the brain of mice with AD-like disease. Confocal microscopy
images of CD45+ leukocytes (red cells) localized in the cortex (A) and choroid plexus (B)
of sex/age-matched wild-type control animals (left panels) and 3xTg-AD mice (right
panels) at 6 months of age. Nuclei are stained with DAPI in blue. Scale bars = 30 μm.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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1 (PECAM-1) also accumulates to higher levels in the plasma of AD pa-
tients compared to control subjects (Nielsen et al., 2007; Vestweber,
2015). PECAM-1 is an endothelial adhesion molecule also found on
platelets and leukocytes, which can interact in a homophilic manner
and mediates leukocyte transmigration during inﬂammation
(Vestweber, 2015). Soluble vascular adhesionmolecules retain the abil-
ity to bind their ligands and may thus activate their counter-receptors
on circulating leukocytes, increasing their adhesion capacity (Lo et al.,
1991; Newman et al., 1993; Wang et al., 2007). For example, soluble
P-selectin may bind and crosslink P-selectin glycoprotein ligand-1
(PSGL-1) or the glycoprotein T cell immunoglobulin and mucin domain
1 (TIM-1), triggering intracellular signaling pathways in leukocytes that
promote adhesion and activate additional pro-inﬂammatory functions
(Wang et al., 2007; Angiari et al., 2014; Angiari and Constantin, 2014).
Therefore, elevated levels of soluble adhesion molecules may represent
a negative predictive factor linking vascular inﬂammation to the pro-
gression of AD.
The role of vascular inﬂammation in AD is supported by our recent
ﬁndings that the expression of E-selectin, P-selectin, VCAM-1 and
ICAM-1 is signiﬁcantly higher in 4-month-old 5xFAD mice than age-
matchedwild-type controls (Zenaro et al., 2015). These adhesionmole-
cules were expressed mainly in the vessels of the meninges and cortex,
but also in the choroid plexi, hippocampus and amygdala of the AD
mice. Similar data were obtained in 3xTg-AD mice, which present
both amyloid and tau pathology: we observed the high-level expression
of all vascular adhesion molecules compared to age-matched controls,
especially E-selectin and P-selectin in the hippocampus and cortex at
6 months of age. Notably, in both transgenic models of AD, adhesion
moleculeswere expressed not only during the early phase of the disease
but also in older animals, suggesting that vascular inﬂammation may
play a continuous pathogenic role (Zenaro et al., 2015). In agreement
with our results, a recent study in Arc/SweAβmice conﬁrmed the strong
upregulation of VCAM-1 and ICAM-1 in the brains of 20–24-month-old
mice compared to wild-type littermates (Ferretti et al., 2016). Interest-
ingly, in both animal ADmodels and human AD patients, the expression
of adhesion molecules was observed in areas burdened by Aβ plaques
and rich in migrated leukocytes (Frohman et al., 1991; Zenaro et al.,
2015; Ferretti et al., 2016). Accordingly, in vitro studies have demon-
strated that Aβ peptides induce the expression of endothelial selectins
and integrin ligands in mouse and human brain endothelial cells (Giri
et al., 2000; Zenaro et al., 2015). In addition, the in vitro stimulation of
human brain endothelial cells with Aβ1-40 promoted the adhesion
and transendothelial migration of monocytes, but this was inhibited
by an antibody to PECAM-1 (Giri et al., 2000; Giri et al., 2002). Therefore,
soluble Aβ oligomers induce the expression of vascular adhesion mole-
cules, which may promote leukocyte adhesion and transmigration dur-
ing AD.
9. Leukocyte trafﬁcking during AD
Leukocytes enter the CNS via three distinct routes: the ﬁrst is from
the blood to the parenchyma through the walls of parenchymal post-
capillary venules; the second is from the blood to the subarachnoid
space through the walls of meningeal vessels; and the third is from
the blood to the CSF across the venule wall and then the stroma and ep-
itheliumof the choroid plexus (Ransohoff et al., 2003). Under inﬂamma-
tory conditions, the ﬁrst two routes are used by leukocytes for CNS
invasion, whereas the last route is considered the major site of CNS
immunosurveillance under physiological conditions (Ransohoff et al.,
2003; Engelhardt and Ransohoff, 2005; Man et al., 2007; Shechter et
al., 2013). Leukocyte extravasation across the inﬂamed endothelium is
a multistep process mediated by adhesion molecules, chemoattractants
and signaling molecules expressed on the surface of brain endothelial
cells (Fig. 2). The migration cascade involves a sequence of adhesion
and activation events including: 1) capture (tethering) and rolling,Please cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
j.nbd.2016.07.007which are mediated by the interactions between selectins and mucins,
and/or between integrins and their ligands from the Ig superfamily; 2)
integrin activation induced by chemoattractants exposed by the endo-
thelial cells through leukocyte G protein coupled receptors (GPCRs);
3) arrest mediated by activated integrins and their counter-ligands; 4)
crawlingmediated by leukocyteβ1 orβ2 integrins and their endothelial
counter-ligands; and 5) paracellular or transcellular diapedesis, mainly
mediated by VE-cadherin, JAMs, CD99 and PECAM-1 (Ley et al., 2007;
Rossi et al., 2011; Vestweber, 2015). During extravasation into the in-
ﬂamed CNS, leukocytes leaving the circulation in post-capillary venules
also need to cross the endothelial basementmembrane and glia limitans
(Farach-Carson et al., 2014). Therefore, during extravasation, leukocytes
need to express glycosidases and proteases allowing them to degrade
the basement membrane molecules (Yadav et al., 2003; Vreys and
David, 2007; Wang et al., 2005; Reichel et al., 2008; Li and Vlodavsky,
2009; Voisin et al., 2009; Vestweber, 2015).
Leukocyte–vascular interactions in CNS venules during inﬂamma-
tion are mediated predominantly by endothelial P-selectin and E-
selectin and their mucin ligands PSGL-1 and TIM-1, as well as leukocyte
integrins that include α4β1 (also known as very late antigen 4, VLA-4)
which bind VCAM-1, and leukocyte integrins αLβ2 (LFA-1) and αMβ2
(Mac-1) which bind ICAM-1 and ICAM-2 (Ley et al., 2007; Rossi et al.,
2011; Angiari et al., 2014; Angiari and Constantin, 2014; Vestweber,
2015). The β2 integrins aremainly involved in neutrophil extravasation
across the inﬂamed BBB, whereas VLA-4 mainly contributes to T cell
trafﬁcking in the CNS (Ransohoff and Engelhardt, 2012; Gorina et al.,
2014; Zenaro et al., 2015). The role of circulating immune system cells
in AD-related brain damage is still unclear, but themigration of cells re-
lated to both innate and adaptive immunity has been observed in the
AD brain (Pietronigro et al., 2016) (Fig. 3).
9.1. Monocyte trafﬁcking during AD
Monocytes are the most widely-studied circulating immune system
cells in AD and they migrate through the BBB into the AD brain in a
CCR2-dependent manner (El Khoury et al., 2007; Naert and Rivest,heimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
9E. Zenaro et al. / Neurobiology of Disease xxx (2016) xxx–xxx2013). CCR2 is a GPCR constitutively expressed in monocytes, at high
levels in the ‘pro-inﬂammatory’ subset, but at lowor undetectable levels
in ‘patrolling’ monocytes, which represent the ‘anti-inﬂammatory’ sub-
set (Pimentel-Coelho et al., 2015). CCL2, the main CCR-2 ligand, is the
most effective activator of the signal transduction pathway leading to
monocyte transmigration and is upregulated in the microvessels of
AD-like mouse brains and the postmortem brains of AD patients
(Ishizuka et al., 1997; Grammas et al., 2001; Simard et al., 2006; El
Khoury et al., 2007; Deshmane et al., 2009; Conductier et al., 2010).
The beneﬁcial role of monocytes in AD relies on the clearance of Aβ,
thus CCR-2 deﬁciency in the Tg2576 and APPSwe/PS1 mouse models
of AD exacerbates amyloidosis and memory deﬁcit (El Khoury et al.,
2007; Naert and Rivest, 2011). In agreement with these data, defective
production of CCR2+ monocytes in APPSwe/PS1 mice is characterized
by cognitive decline, accumulation of soluble Aβ and disruption of syn-
aptic activity (Naert and Rivest, 2012; Naert and Rivest, 2013). Further-
more, intravital two-photonmicroscopy studies indicate that patrolling
CCR2−monocytes are attracted to and crawl onto the luminal walls of
Aβ+veins and that their selective removal in APP/PS1mice signiﬁcantly
increases the Aβ load in the cortex and hippocampus, suggesting that
patrolling monocytes can naturally target and eliminate Aβ within the
lumen of veins (Michaud et al., 2013). Aβ1-42 is an activating and che-
motactic factor formonocytes that induces the transmigrationof human
monocytes in an in vitroBBBmodel (Fiala et al., 1998). Furthermore, cul-
tured human peripheral monocytes stimulated with Aβ1-42 secrete
pro-inﬂammatory cytokines including TNFα, IL-6, IL-1β and IL-12, as
well as MCP-1, MIP-lα, MIP-1β, and IL-8, suggesting that they may
have a detrimental role in AD (Fiala et al., 1998). The three-dimensional
reconstructionof spatial relationships betweenvessels, Aβdeposits, and
cells of the monocyte/microglial lineage in Tg2576 mice suggested that
monocytes/macrophages recruited from the blood play a role in ﬁbrillar
Aβ deposition (Wegiel et al., 2004). Despite the evidence discussed
above, two studies have recently challenged the view that circulating
monocytes help to clear Aβ in ADmodels. The replacement of brain-res-
ident myeloid cells with circulating peripheral monocytes in mouse
models of cerebral β-amyloidosis showed that monocyte repopulation
does not modify the amyloid load, arguing against a long-term role for
peripheral monocytes in Aβ clearance (Prokop et al., 2015; Varvel et
al., 2015).
9.2. Neutrophil migration in the AD brain
Neutrophils are highly reactive cells that release ROS, enzymes, NETs
and cytokines, and can thus cause long-term collateral tissue damage
even if they do not accumulate substantially within tissues during
chronic sterile inﬂammation. Indeed, previous studies (including our
own) have shown that neutrophils do not need to accumulate in high
numbers in order to induce tissue damage, and that adhesion on the
vesselwall without transmigration is sufﬁcient to induce endothelial in-
jury (Zarbock and Ley, 2008; Fabene et al., 2008; DiStasi and Ley, 2009).
Our recent data show that neutrophils play a role in the induction of
neuropathological changes and memory deﬁcit in 5xFAD and 3xTg-AD
mice (Zenaro et al., 2015).We found that neutrophils adhered inside ce-
rebral vessels or migrated in the parenchyma in higher numbers in the
ADmodels (at the onset ofmemory deﬁcit) compared towild-type con-
trols, suggesting these cells may play a role in AD pathogenesis (Fig. 2).
Extravasated neutrophils produced NETs and IL-17, suggesting they
may harm the BBB and neural cells (Zenaro et al., 2015). Two-photon
laser-scanning microscopy revealed that neutrophils adhere and crawl
inside blood vessels and migrate into the parenchyma in areas with
Aβ deposits, further supporting a role for neutrophils in AD (Fig. 2)
(Zenaro et al., 2015). Accordingly, other recent imaging studies have
shown that Gr1+ cells extravasate through the BBB in the brain paren-
chyma of 5xFAD mice and migrate towards Aβ plaques, suggesting a
role for Aβ in neutrophil recruitment during AD (Baik et al., 2014). Fur-
thermore, we found that soluble oligomeric Aβ1-42 triggers the rapid,Please cite this article as: Zenaro, E., et al., The blood-brain barrier in Alz
j.nbd.2016.07.007integrin-dependent adhesion of human and mouse neutrophils on ﬁ-
brinogen and ICAM-1, which are both integrin ligands (Fig. 2). Notably,
Aβ1-42 also triggers the LFA-1 integrin high-afﬁnity state in human
neutrophils, providing an explanation for the tendency of neutrophils
to arrest in areas with Aβ deposits in vivo. LFA-1 integrin is necessary
for neutrophil adhesion in brain vessels, and neutrophils from LFA-1 de-
ﬁcientmice are unable to adhere or crawl in blood vessels and thus can-
not transmigrate in the brain parenchyma of AD mice. Accordingly,
blocking LFA-1 integrin andneutrophil adhesion has a therapeutic effect
on mouse models of AD, suggesting a prominent role for LFA-1 integrin
in neutrophil trafﬁcking and AD pathogenesis (Zenaro et al., 2015).
Neutrophils also adhere intravascularly in the brains of AD patients
and migrate near areas with Aβ deposits suggesting that Aβ inﬂuences
the microenvironmental positioning of neutrophils inside the AD brain
(Savage et al., 1994; Zenaro et al., 2015). As shown in transgenic mice
with AD-like disease, they produce intravascular NETs, which may be
harmful to the endothelial cells, suggesting these cells may promote
the loss of BBB integrity and thus the pathogenesis of AD in humans
(Fig. 2) (Zenaro et al., 2015).
9.3. Lymphocyte accumulation in the AD brain
Lymphocytes can also cross the BBB during AD. Both CD4+ and
CD8+ T cells were observed adhering to the vascular endothelium, or
migrating into the parenchyma, of AD patients (Itagaki et al., 1988;
Rogers et al., 1988; Togo et al., 2002; Town et al., 2005). The number
of these cells was higher in AD patients than in healthy, age-matched
controls, with the majority of the T cells inﬁltrating the hippocampus
and other limbic structures, which are the most severely affected by
AD (Itagaki et al., 1988; Rogers et al., 1988; Togo et al., 2002; Town et
al., 2005). Furthermore, MCI and mild AD patients contained a greater
number of activated CD4+ and CD8+ T cells in the CSF, with the propor-
tion of activated CD8+ T cells showing the highest increase, supporting
the hypothesis that activated T cells migrate from the blood into the
brain during AD (Lueg et al., 2015).
Similarly, T cells also inﬁltrate into the brains of APP/PS1 mice, and
may secrete interferon gamma (IFNγ) or IL-17, suggesting that the re-
lease of these cytokines could accelerate AD neuropathology (Browne
et al., 2013). The infection of APP/PS1 mice with the Gram-negative re-
spiratory pathogen Bordetella pertussis promoted inﬁltration by T cells
and natural killer cells producing IFNγ and IL-17, accompanied by in-
creased glial activation and Aβ deposition. This suggests that peripheral
inﬂammationmay favor the entry of circulating activated T cells into the
brain, which may in turn exacerbate AD pathology (McManus et al.,
2014). Brain amyloidosis promotes T cell migration into the brain and
the expression of vascular adhesion molecules in brain vessels
(Ferretti et al., 2016). Cells of the adaptive immune system play a nega-
tive role duringAD, andAPP/PS1 transgenicmice crossbredwith recom-
bination activating gene 2 (RAG2) knockout mice lacking functional B
and T cells are characterized by limited brain Aβ pathology, enhanced
microgliosis and the more efﬁcient phagocytosis of Aβ peptide aggre-
gates (Späni et al., 2015). Together, these data suggest that activated T
cells play a detrimental role in AD pathology and that interfering with
activated T cell development or activity may have a beneﬁcial impact.
Accordingly, recent studies suggest that regulatory T (Treg) cells,
which suppress adaptive T cell responses and T cell activation, play a
beneﬁcial role in AD models during the early phase of the disease, by
slowing disease progression and modulating microglial responses to
Aβ deposition. (Dansokho et al., 2016). However, Treg cells play a nega-
tive role in old 5xFADmice (Baruch et al., 2015), and the systemic inhi-
bition of Treg cell function for one week was sufﬁcient to signiﬁcantly
reduce Aβ accumulation in these mice during the later stages of AD
characterized by robust cerebral Aβ plaque pathology. The role of T
cell populations at different AD stages therefore remains to be deter-
mined, and future studies should aim to clarify the role of these cells
in AD pathology.heimer's disease, Neurobiol. Dis. (2016), http://dx.doi.org/10.1016/
10 E. Zenaro et al. / Neurobiology of Disease xxx (2016) xxx–xxxThe mechanisms controlling T cell recruitment in the AD brain are
not well understood, but transforming growth factor β (TGF-β), endo-
thelial activation and Aβ deposition may each play a role. The overex-
pression of TGF-β1 in the brains of wild-type mice or transgenic AD-
like mice promotes T cell inﬁltration in the meninges and parenchyma
after immunization with Aβ1-42 (Buckwalter et al., 2006). Moreover,
in vitro studies suggest that Aβ1-42 induces the release of TNFα by
microglial cells, which in turn promotes major histocompatibility com-
plex I expression on the brain endothelium followed by the
transendothelial migration of T cells (Yang et al., 2013). Accordingly, T
cells together with macrophages and monocytes were observed in
leptomeningeal and cortical vessels, associated with CAA, suggesting
that Aβ and CAA favor T cell migration into the AD brain (Yamada et
al., 1996). In agreement with these results, the injection of Aβ into the
rat hippocampus activates endothelial cells through the engagement
of RAGE and induces CCR5, whichmay in turn promote T cell migration
into the brain (Li et al., 2009). Additionally, peripheral T cells in AD pa-
tients overexpress MIP-1α, which may bind to CCR5 on the surface of
brain endothelial cells, potentially supporting T cell migration through
endothelial tight junctions into the CNS (Man et al., 2007). MIP-1α is
one themost common chemokines expressed during CNS inﬂammation
(Xia and Hyman, 1999; Mennicken et al., 1999) and CCR5 is expressed
on brain endothelial cells in aged AD patients (Xia et al., 2000; Mo et
al., 2003). Notably, MIP-1α production by activated microglia promotes
T cell migration in the CNS in EAEmodels, and we suggest this may also
be the case in AD (Karpus et al., 1995). Furthermore, circulating T cells in
AD patients also overexpress CXCR2, a chemokine receptor that is wide-
ly expressed on immune system cells that may promote their
transendothelial migration (Liu et al., 2010). The inﬂammatory re-
sponse stimulated by T cells that have migrated into the AD brain may
activate microglia and astrocytes and may recruit other inﬂammatory
cells that are potentially harmful to the CNS, thus exacerbating the path-
ogenesis of AD.
10. Concluding remarks
BBB dysfunction during AD inﬂuences Aβ clearance and endothelial
transport, impairs endothelial cell and pericyte functions, affects TJ in-
tegrity, activates glial cells and facilitates the recruitment of leukocytes
in the brain. However, themechanisms that regulate BBB breakdown in
the context of chronic neuroinﬂammation during AD still remain to be
elucidated. The role of circulating immune system cells in AD-related
brain damage is poorly understood, and future studies are needed to de-
termine how speciﬁc populations of cells representing the innate and
adaptive immune systemspromote the cognitive deﬁcit and neuropath-
ological changes in AD. In this sense, advanced imaging techniques will
help to provide insights into themechanisms controlling leukocyte–en-
dothelial interactions in AD, and may lead to the development of novel
therapeutic strategies based on the inhibition of integrins, selectins,mu-
cins and other adhesionmolecules, as well as chemoattractants to delay
the progression of the disease. Plasmatic adhesion molecule
ectodomains may offer valuable biomarkers of neuroinﬂammation
and endothelial dysfunction, and more studies are needed to correlate
circulating soluble adhesion molecules with BBB integrity and the se-
verity of AD.
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